Catheter ablation of atrial fibrillation in patients with diabetes mellitus

Authors :: Allen Wang, MD
Tracy Truong, MB
Eric Black-Maier, MD
Cynthia Green, PhD
Kristen B. Campbell, PharmD
Adam S. Barnett, MD
Janice Febre, BSN, RN
Zak Loring, MD, MHS
Sana M. Al-Khatib, MD, MHS, FHRS
Brett D. Atwater, MD
James P. Daubert, MD, FHRS
Camille Frazier-Mills, MD, MHS
Donald D. Hegland, MD
Kevin P. Jackson, MD
Larry R. Jackson, MD
Jason I. Koontz, MD, PhD
Robert K. Lewis, MD, PhD
Sean D. Pokorney, MD, MBA
Albert Y. Sun, MD
Kevin L. Thomas, MD
Tristam D. Bahnson, MD, FHRS
Jonathan P. Piccini, MD, MHS, FHRS
Source :: Heart Rhythm O2, Vol 1, Iss 3, Pp 180-188 (2020)
Publication Year :: 2020
Publisher :: Elsevier, 2020.
Abstract: Background: Diabetes mellitus (DM) is an independent risk factor for atrial fibrillation (AF). Few studies have compared clinical outcomes after catheter ablation between patients with and those without DM. Objective: The purpose of this study was to compare AF ablation outcomes in patients with and those without DM. Methods: We performed a retrospective analysis of 351 consecutive patients who underwent first-time AF ablation. Clinical outcomes included freedom from recurrent atrial arrhythmia, symptom burden (Mayo AF Symptom Inventory score), cardiovascular and all-cause hospitalizations, and periprocedural complications. Results: Patients with DM (n = 65) were older, had a higher body mass index, more persistent AF, more hypertension, and larger left atrial diameter (P